ANLN has been shown to be a biomarker of unfavourable prognosis and is related to aggressive tumour phenotypes.49 Anillin plays a regulatory role in the cell cycle and an important role in the invasion of pancreatic and breast cancers.50, 51 ANLN has been developed as a prognostic marker based on immunohistochemistry (IHC) and is clinically applicable to hepatocellular carcinoma.52 Suzuki et al53 explored the importance of ANLN in lung cancers using cDNA microarrays and found that the growth of NSCLC was inhibited by ANLN small interfering RNAs. Here, ANLN is linked to breast carcinoma.